Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04816526 · ClinicalTrials.gov registry record · Phase 2
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
A Phase 2 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04816526 is a Phase 2 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT04816526, a Phase 2 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
Interventions
- BIOLOGICAL Descartes 08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2022-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04816526
The ClinicalTrials.gov registry entry for NCT04816526 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Descartes 08 is the first listed.
NCT04816526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04816526 about?
NCT04816526 is a clinical study titled "Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy". To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
What is the current status of trial NCT04816526?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2021-12-01. Estimated completion is 2022-11-03.
What interventions are being tested in trial NCT04816526?
The interventions under investigation include: Descartes 08 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04816526?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.